We can’t show the full text here under this license.
Abstract
Among 144 patients, 11 taking semaglutide or tirzepatide for over six months had residual gastric content during esophagogastroduodenoscopy.
- A significant association was found between GLP-1 usage for more than six months and the presence of residual gastric content (p<0.001).
- Of the 12 patients on long-term GLP-1 therapy, 91.7% exhibited residual gastric content.
- No residual gastric content was observed in the 132 patients who did not meet the inclusion criteria.
- A moderate positive association was noted between residual gastric content and age.
- A weak negative association was identified between residual gastric content and body mass index (BMI).
- There were no procedure-related complications, and all patients were discharged on the same day.
Simplified